Gluconic Acid

Gluconic Acid

SCHEMBL20547381

O=C([O-])C(O)C(O)C(O)C(O)CO.O=C([O-])C(O)C(O)C(O)C(O)CO.[Ca+2]

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.91
PDE4A P27815 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.52
TDP1 Q9NUW8 1/20 0.50
USP2 O75604 1/20 0.50
SLCO1B1 Q9Y6L6 1/20 0.50
KDM4E B2RXH2 2/20 0.38
OR51E2 Q9H255 1/20 0.35
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CA4 P22748 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gluconic Acid SCHEMBL24132 1.00 LMNA (0.91) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL28580751 1.00 LMNA (0.91) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL28093047 1.00 LMNA (0.91) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL30760667 1.00 LMNA (0.91) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL29661854 1.00 LMNA (0.91) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL23415272 1.00 LMNA (0.91) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL16180766 1.00 LMNA (0.91) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL409772 0.98 LMNA (0.87) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL4624626 0.98 LMNA (0.87) LMNAPDE4AL3MBTL1TDP1USP2
Gluconic Acid SCHEMBL2030434 0.98 LMNA (0.95) LMNAPDE4AL3MBTL1TDP1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111269978-B Human ApoE genotyping detection kit 深圳市天大生物医疗器械有限公司 2020-12-08 CN claimed
CN-111269978-A Human ApoE genotyping detection kit 深圳市天大生物医疗器械有限公司 2020-06-12 CN claimed
CN-108936689-A Adjust the oral solution and preparation method thereof of immunity 江西皓宇生物科技有限公司 2018-12-07 CN claimed
CN-108289860-A Preparation for sticking to tooth or tooth periphery 株式会社 LG 生活健康 2018-07-17 CN claimed
CN-103479652-B Children's four-vitamin calcium gluconate effervescent tablets and preparation method thereof FUZHOU NEPTUNUS FUYAO PHARMACEUTICAL CO LTD 2014-12-03 CN claimed
CN-103479652-A Children's four-vitamin calcium gluconate effervescent tablets and preparation method thereof FUZHOU NEPTUNUS FUYAO PHARMACEUTICAL CO LTD 2014-01-01 CN claimed
CN-101869302-B Micro-emulsion calcium preparation and preparation method as well as application thereof NIU XIN 2013-01-30 CN claimed
US-20260115122-A1 PERSONAL CARE COMPOSITIONS COMPRISING PANCRATIUM MARITIMUM Galderma Holding SA (CH) 2026-04-30 US disclosed
EP-4547340-A1 PERSONAL CARE COMPOSITIONS COMPRISING PANCRATIUM MARITIMUM Galderma Holding SA (CH) 2025-05-07 EP disclosed
US-20250032388-A1 PERSONAL CARE COMPOSITIONS FOR SENSITIVE SKIN AND METHODS OF USE Galderma Holding SA (CH) 2025-01-30 US disclosed
WO-2024003594-A1 PERSONAL CARE COMPOSITIONS COMPRISING PANCRATIUM MARITIMUM Galderma Holding SA (CH) 2024-01-04 WO disclosed
WO-2023192538-A1 PERSONAL CARE COMPOSITIONS FOR SENSITIVE SKIN AND METHODS OF USE Galderma Holding SA (CH) 2023-10-05 WO disclosed
CN-116209419-A Hair composition, auxiliary agent composition, and hair treatment method 株式会社玫丽盼 2023-06-02 CN disclosed
CN-101574334-A Method for preparing calcium gluconate preparation HARBIN PHARMACEUTICAL GROUP SA (CN) 2009-11-11 CN disclosed
CN-101485824-A Chinese medicament preparation for tonifying kidney and benefiting brain as well as preparation method and novel use thereof BEIJING ASIA EAST BIO PHARM CO (CN) 2009-07-22 CN disclosed
CN-1957908-A Method for preparing gel of zinc calcium gluconate ZHONGJI PHARMACEUTICAL CO LTD (CN) 2007-05-09 CN disclosed
CN-1927196-A Preparing process for freeze-dried calcium gluconate powder injection ZHANG WEIQUN (CN) 2007-03-14 CN disclosed
CN-1857229-A Medicine dragee suitable for children to take and its preparing method MAO XIAOMIN (CN) 2006-11-08 CN disclosed
CN-1830460-A Xuesaitong (thrombus clearout) chewing tablet and its preparation method TAN ANDE (CN) 2006-09-13 CN disclosed
CN-1799541-A Soybean isoflavone soft capsule and its preparation process TIANJIN ZHONGXIN PHARMACEUTICAL GROUP CO LTD (CN) 2006-07-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115122-A1 PERSONAL CARE COMPOSITIONS COMPRISING PANCRATIUM MARITIMUM B3GNT2, GLA, AMPD2 LMNA 2668/4885PDE4A 989/4885L3MBTL1 2895/4885
US-20250032388-A1 PERSONAL CARE COMPOSITIONS FOR SENSITIVE SKIN AND METHODS OF USE GLA, CUTA, COLGALT1 LMNA 104/4885PDE4A 2503/4885L3MBTL1 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.